UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 14, 2026**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	**000-50761**	**11-3146460**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
14 Plaza Drive, Latham, New York		**12110**
(Address of Principal Executive Offices)		(Zip Code)

(518) 795-1400

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ANGO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 - Regulation FD Disclosure.

On January 14, 2026, James Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. ("AngioDynamics"), presented at the J.P. Morgan 44th Annual Healthcare Conference. The presentation slides are furnished herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Item 9.01 – Financial Statements and Exhibits.

(d) *Exhibits*.

Exhibit No.	Description
99.1	Presentation slides for the J.P. Morgan 44th Annual Healthcare Conference, dated January 14, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: January 14, 2026

By: /s/ Lawrence T. Weiss
Name: Lawrence T. Weiss
Title: Senior Vice President, Chief Legal Officer and Corporate Secretary

angiodynamics

J.P. Morgan

44th Annual Healthcare Conference

January 14, 2026

Jim Clemmer, President & CEO

Forward looking statements

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynar future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth o and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "belie "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarc performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, t AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technolog that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substar resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results o litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and prod changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general mc market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioD obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any fo statements for any reason.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends i business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared i with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and st compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performa Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using thes measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP mea prepared in accordance with GAAP.

AngioDynamics

Our proven success positions us for sustained growth and profitability in key marke

2020 - Today

Drove Performance and Built a More Dynamic Growth Focused Company

Sharpened Portfolio Focus

- Active portfolio management to scale high-growth MedTech opportunities

Accelerated Innovation

- Expanded MedTech leadership through innovation, strategic M&A, clinical investment, and meaningful physician engagement

Strengthened Financial Position

- Delivered accelerated growth, streamlined operations, and improved margin performance

Med Tech Growth & Sales Mix (%)



Today & Beyond

Positioned for Sustained Profitable Gr

Accelerating Commercial Investment

- Building a stronger go-to-market engine in Cardiovascula capture growth opportunities

Fueling Innovation

- Increasing R&D investment to deliver breakthrough techn term value

Expanding Market Potential

- Growing TAM as clinical data unlocks new indications ac franchises

Robust Product Pipeline

- Leveraging leading platforms to accelerate innovation a sustained expansion in attractive, high-growth markets

Unrivaled Innovation

Our synergistic portfolio is focused on providing comprehensive solutions to help tr patients within two of the largest global healthcare markets



Cardiovascular Arterial

Since its launch in September 2020, Auryon has been used in nearly 150,000 proce and surpassed $200M in cumulative sales

MARKET DYNAMICS



Peripheral Artery Disease (PAD)

- Hospital market growth fuels ASP stability
- New and expanded reimbursement coverage solidifies atherectomy's pl algorithms
- AMBITION BTK further positions us for market expansion

Auryon is versatile and effective at treating all types of lesions both throug radial approaches

Comprehensive Treatment Capability

- Effectively addresses all lesion types, including severe calcification and in-stent

Precision and Safety

- Optimized technology delivers energy without thermal damage, with built-in as embolization risk

Efficiency and Proven Outcomes

- Portable, easy-to-use system with clinically validated performance and high pa

AURY

Cardiovascular Venous

Venous Thromboembolism (VTE) represents an attractive, high growth, underpenet market opportunity

MARKET DYNAMICS



PE + DVT = Venous Thromboembolism (VTE)

- Mechanical Thrombectomy for **PE** is estimated to have penetrated ~20%
- Mechanical Thrombectomy for **DVT** is estimated to have penetrated ~1

Right Heart Cardiac Thrombus & Emboli

- Growth is driven by rising increase in endocarditis and an aging populat
- More interventionalists embrace percutaneous techniques and the struc market is expanding

ANGIOVAC

ALPHAVAC

Mechanical Thrombectomy

Proprietary funnel cannula technology with the ability to have aspiration and simul reinfusion with AngioVac or off-circuit manual aspiration control with AlphaVac

AlphaVac Indicated for Treatment of Pulmonary Embolism

ALPHAVAC

- Minimally invasive treatment used to treat PE and remove large blood clots, or thrombi, and other material from the venous system (veins), including the pulmonary arteries
- Manual aspiration control enables precise suction, enhanced physician control, and improved maneuverability for wireless navigation between the PA's



Complete system significantly improving reduction in clot burden vs. competitive technologies

*Actual case result

Aspiration & Simultaneou

ANGIOVAC

- Minimally invasive treatment large blood clots, or thrombi, material from the venous syst
- On-circuit aspiration provide via percutaneous access by reinfusing blood back in the minimizing blood loss

APEX – AV Pivotal Study

AlphaVac received FDA clearance for PE following APEX-AV study demonstrating
and significantly improved reduction in clot burden vs. competitive technologies

APEX-AV

Number of Sites	**25 US Sites**
Number of Patients	**122**
Timeline	**Oct. 2022 – Dec 2023**

Significant reduction in the RV/LV ratio
- Significant improvement in the RV function

Significant reduction in clot burden
- Large funnel size (33 Fr) may aid in reducing the clot burden

Procedure efficiency
- Atraumatic tip provides easy and efficient navigation in the PAs
- Ability to minimize blood loss
- Short procedure time

	APEX (AngioDynamics)	FLARE (Inari/Stryker)	EXTRACT-PE (Penumbra)
Reduction in Clot Burden	**35.1%**	9.3%	11.3%

Prostate Cancer

Backed by real world evidence and compelling clinical data, NanoKnife is a one-
technology poised to change the standard of care of men with prostate cancer

MARKET DYNAMICS



Prostate Cancer is Prevalent, On the Rise & Debilitating

- The most diagnosed male cancer in 112 countries, including the U.S.
- Incidence projected to double by 2040
- Focal therapy is less than 7% penetrated into the Intermediate Risk addressable m

Only Function-preserving Therapy that Uses Electricity to Destroy Prostate Tumors

- Destroys targeted tissue with precise margins, preserving vital structures and tissue integrity
- Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kin technology poised to change the standard of care of men with prostate cancer
- NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation

NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE



Irreversible Electroporation (IRE)

Preserves the underlying structure of tissue giving physicians a more precise tool

NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE

- **Only IRE device FDA cleared** for prostate tissue
- Efficiently **treats all segments** of the prostate
- **Easy clinical integration**
- Significantly **reduces quality of life side-effects** caused by other therapeutic options

PROBE PLACEMENT

NanoKnife can be confidently used in all segments of an organ.





DECELLULARIZATION

Destroys targeted tissue with precise treatment margins.



NON-THER

Spares vital structures b structural integrity

REVASC

Facili tissu p

PRESERVE Pivotal Study

NanoKnife safely & effectively treats prostate tumors while avoiding the high incide of erectile dysfunction and incontinence associated with radical surgery and radia

PRESERVE

Number of Sites	**17 US Sites**
Number of Patients	**121**
Follow Up	**12 Months**

Efficacy

84% of patients were free from clinically significant in-field disease

Safety

3.3% of patients had a device related SAE, all of which resolv

Change from baseline at 1 year

	IRE	Radical Surgery	Radiation Therapy
Erectile Function	**(9%)**	(51%)	(30%)
Urinary Continence	**(1.2%)**	(41%)	(8%)

We will continue to follow patients in PRESERVE study and collect data

National Recognition for Oncology

Leveraging TIME and AARP to elevate awareness and credibility

TIME's Best Inventions of 2025

TIME BEST INVENTIONS 2025

- Recognized as a top innovation in Medical & Healthcare
- Highlights AngioDynamics' leadership in minimally invasive oncology
- National visibility and validation of our breakthrough technology

AARP® Marketing Partner


BRANDAMP BY AARP

PAID CONTENT NANOKNIFE

A NEW WAY FORWARD IN PROSTATE TUMOR CARE

Preserve Your Health and Quality of Life

Chances are, you know someone who's had prostate cancer, since it's one of the most common cancers diagnosed in men around the world.[1] In fact, 1 in 8 men will be diagnosed with prostate cancer.[2] Many men experience fear around the diagnosis as well as the implications of treatment – which is understandable. Previously, patients had to choose between radical surgery or radiation that may negatively impact erectile and urinary function.[3,4] Today, a new technology is expanding the treatment options available to men.

Meet Paul

"I was playing golf a week and a half after I had the procedure... I was able to walk and swing the same way I was swinging... just like I never had the procedure." – Paul

Scan the QR code to watch video and see how the NanoKnife Procedure works.

Science at Work

The NanoKnife System is the only minimally invasive therapy that precisely targets the prostate tumor with electrical pulses, destroying cells while helping to preserve sexual function and urinary continence.[5]

- Fast and Efficient – an outpatient procedure that takes about an hour and has a rapid recovery time[6]
- Safe and Effective – helps preserve urinary control and erectile function[7]
- Conserve Future Options – procedure can be repeated if necessary and does not interfere with other treatment options[8]

What to Expect

The NanoKnife System therapy is an outpatient procedure performed under general anesthesia by specially-trained urologic surgeons at a hospital or ambulatory surgery center. Thin, minimally invasive needles will be placed around the tumor, electrical pulses are delivered between the needles, destroying the prostate tumor. Post-procedure recovery will vary, but expect a catheter to remain for a few days. Follow-up visits will confirm the effectiveness of treatment. If the NanoKnife System is right for you, then your doctor will provide you with detailed information related to your procedure.

Wondering if the NanoKnife System is a good option for you or your loved one?

The ideal candidate has prostate tumors visible on imaging. Consult with a specialist who has experience with the NanoKnife System. Insurance coverage can vary depending on your provider. There's a different way forward, don't let fear of treatment or side effects hold you back.

Take the next step. Use the physician locator at NanoKnife.com/AARP to find a NanoKnife doctor near you.

AARP does not recommend individual healthcare providers

PRINT AD feat
Magazine
(October/Novemb
Breakthroughs" iss
- Focus on awa credibility
- 23+ million rea

DIGITAL BANN
- Run-of-site

RUN-OF-SITE V
- Patient Metho

Strong Product & Clinical Pipeline

Leveraging our leading platforms to fuel innovation, market expansion, and long-te shareholder value in key growth markets



Compelling FY2026 Financial Outlook

Supported by balance sheet strength

FY 2026 Net Sales ($M)



FY 2026 Financial Guidance*

Metric	Action	Prior Guidance	
Net Sales	Increased	$308 - $313M	
Med Tech Net Sales Growth	*Unchanged*	*+14 – 16%*	
Med Device Net Sales Growth	*Increased*	*Flat*	
Gross Margin	Unchanged	53.5 – 55.5%	
Adjusted EBITDA	Increased	+$6.0 - $10.0M	
Adjusted EPS	Unchanged	($0.33) – ($0.23)	(
Free Cash Flow	Unchanged	Positive for Full Year	Po

Balance Sheet Strength Supports Long Term Strate

- **$41.6M** in Cash at Nov 30, 2025
- **Zero debt on balance sheet with flexibility** from revol

*Guidance was issued in conjunction with fiscal Q2 FY 2026 earnings call on Jan 6, 2026

AngioDynamics Investment Summary

Attractive MedTech Platforms in High-Value Markets

Our MedTech segment operates in large, growing clinical markets, supported by differentiated technologies and proven clinical outcome

Demonstrated Execution and Portfolio Discipline

We have a strong track record of active portfolio management, disciplined R&D investment, successful clinical and regulatory expansion, customer-centric sales and marketing execution.

Self-Funded Growth Model

Our Med Device segment generates cash flow that funds targeted investments to accelerate MedTech innovation and growth.

Strong, Debt-Free Balance Sheet

We maintain a solid financial foundation with no debt, providing flexibility to invest, scale, and pursue strategic opportunities.

Clear Path to Profitability and Cash Generation

We expect to achieve adjusted EBITDA positivity by FY2025 and cash flow positivity by FY2026, reflecting improving operating leverage and margin expansion.

Positioned for Sustainable, Long-Term Value Creation

With focused strategy, financial strength, and innovation-driven growth, AngioDynamics is well positioned to deliver durable revenue growth and profitability over the long term.

angiodynamics

J.P. Morgan

44th Annual Healthcare Conference

January 14, 2026

Jim Clemmer, President & CEO